Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy
Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection....
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Journal of hepatology
Year: 2019, Volume: 70, Issue: 5, Pages: 1008-1015 |
| ISSN: | 1600-0641 |
| DOI: | 10.1016/j.jhep.2018.12.022 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.jhep.2018.12.022
|
| Author Notes: | Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, on behalf of the Hepatitis Delta International Network (HDIN) |
| Summary: | Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials. |
|---|---|
| Item Description: | Gesehen am 22.05.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1600-0641 |
| DOI: | 10.1016/j.jhep.2018.12.022 |